Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04895631 · ClinicalTrials.gov registry record · Phase 3
18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas
A Phase 3 study of Hyperparathyroidism, Primary, sponsored by Thomas Hope.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT04895631: Recruiting Phase 3 study of Hyperparathyroidism, Primary, sponsored by Thomas Hope.
NCT04895631 is a Phase 3 study of Hyperparathyroidism, Primary that is actively recruiting participants, run by Thomas Hope. The registered enrollment target is 140 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04895631, a Phase 3 study of Hyperparathyroidism, Primary, is actively recruiting participants, sponsored by Thomas Hope.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective single arm single center Phase III study evaluating the ability of 18F-fluorocholine to detect the location of parathyroid adenomas.
Primary Outcome
Sensitivity of 18F-fluorocholine PET for the detection of abnormal parathyroid adenomas confirmed by pathology as compared to sestamibi imaging. Location of parathyroid adenoma at imaging as read by three blinded readers, will be correlated to the location at surgery. True positive will be defined as an adenoma on imaging in the same location as seen at surgery. Sensitivity will be reported by individual reader.
Conditions Studied
Interventions
- DRUG 18F-Fluorocholine
- PROCEDURE Positron emission tomography (PET)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
What NCT04895631 shows while recruiting
NCT04895631 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Hyperparathyroidism, Primary appearing as the primary indexed condition, and to 2 interventions - of which 18F-Fluorocholine is the first listed.
NCT04895631 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04895631 about?
NCT04895631 is a clinical study titled "18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas". This is a prospective single arm single center Phase III study evaluating the ability of 18F-fluorocholine to detect the location of parathyroid adenomas.
What is the current status of trial NCT04895631?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2021-06-30. Estimated completion is 2027-06-30.
What conditions does trial NCT04895631 study?
This clinical trial studies the following conditions: Hyperparathyroidism, Primary.
What interventions are being tested in trial NCT04895631?
The interventions under investigation include: 18F-Fluorocholine (DRUG), Positron emission tomography (PET) (PROCEDURE).
Who is sponsoring clinical trial NCT04895631?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04895631 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperparathyroidism, Primary
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04895631's enrollment target sits among peer trials
140 1566th of 2000 higher than 424 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI